Dianthus Therapeutics, Inc. /DE/ cotiza a 78.44 USD y tiene una capitalización bursátil de $4.3B. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active…
| Periodo | 2026-11 | 2026-08 | 2026-05 | 2026-03 |
|---|---|---|---|---|
| Real | — | $-0.90 | $-0.85 | $-1.43 |
| Estimado | $-0.95 | $-0.91 | $-1.10 | $-1.03 |
| Sorpresa | — | +1.1% | +22.7% | -38.8% |
| Métrica | DNTH | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | -8739.3% | -38.6% | -8700.7% |
| Net Margin | -7973.3% | -33.6% | -7939.8% |
| FCF Margin | -6349.4% | -13.9% | -6335.5% |
| ROE | -32.9% | -40.4% | +7.5% |
| ROA | -30.6% | -32.0% | +1.4% |
| Current Ratio | 13.32 | 2.84 | +10.48 |
| Debt / Equity | — | 0.28 | — |